← Back to Search

Other

Arm 5 for Obesity (VISTA Trial)

Phase 2
Waitlist Available
Led By Prof Melanie Davies, MBChB MD
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Adults ≥ 18 years of age.
(i) Hypertension (ii) Dyslipidemia or hyperlipidemia (iii) CV disease (iv) Obstructive sleep apnea
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 26 and week 36
Awards & highlights

Summary

A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) who have at least 1 weight-related comorbidity

Who is the study for?
This trial is for adults at least 18 years old who are living with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with at least one weight-related health issue. Key eligibility details will be provided by the study team.
What is being tested?
The trial is testing AZD5004, a new oral medication, against a placebo over a period of 36 weeks to see its effects on individuals with obesity or overweight conditions. Participants are randomly assigned to either the drug or placebo group.
What are the potential side effects?
Specific side effects of AZD5004 aren't listed here but typically may include digestive issues, changes in appetite, fatigue, and potential metabolic disturbances. The exact side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 26 and week 36
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 26 and week 36 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of participants with weight loss ≥ 5% from baseline weight
Secondary study objectives
Absolute change from baseline in body weight
Percent change in body weight from baseline
Proportion of participants with weight loss ≥ 10% as well as ≥ 15%
+1 more

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm 5Experimental Treatment1 Intervention
Active IMP
Group II: Arm 4Experimental Treatment1 Intervention
Active IMP
Group III: Arm 3Experimental Treatment1 Intervention
Active IMP
Group IV: Arm 2Experimental Treatment1 Intervention
Active IMP
Group V: Arm 1Experimental Treatment1 Intervention
Active IMP
Group VI: Arm 6Placebo Group1 Intervention
Matching placebo for each of the 5 active arms

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,306 Previous Clinical Trials
288,625,183 Total Patients Enrolled
29 Trials studying Obesity
12,392 Patients Enrolled for Obesity
Prof Melanie Davies, MBChB MDPrincipal InvestigatorDiabetes Research Centre Leicester Diabetes Centre - Bloom University of Leicester
~190 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top